SCHEDULE: FMR LLC Discloses 5.6% Stake in Day One Biopharma

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Day One Biopharmaceuticals Inc. as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, through various entities, beneficially own an aggregate of 5,717,007.68 shares of Day One Biopharmaceuticals Inc. common stock.
• This ownership represents 5.6% of the total outstanding common stock of Day One Biopharmaceuticals Inc.
• FMR LLC holds sole voting power over 5,702,209.00 shares and sole dispositive power over 5,717,007.68 shares.
• Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same aggregate amount of shares with sole dispositive power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• This filing is Amendment No. 5 to previous Schedule 13G statements by FMR LLC and Abigail P. Johnson.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor like FMR LLC maintaining a 5.6% stake suggests continued confidence in Day One Biopharmaceuticals Inc. without any indication of activist intent.

Positives

• A major institutional investor, FMR LLC (Fidelity), maintains a significant 5.6% stake in Day One Biopharmaceuticals Inc., indicating continued confidence in the company.
• The holding is for investment purposes in the ordinary course of business, not for activist intentions to change control, suggesting a stable long-term investment.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
• Stephanie J. Brown, Duly authorized under Power of Attorney, signed on behalf of FMR LLC and Abigail P. Johnson.

Industry Context

StockSavvy.ai notes that institutional ownership by major asset managers like FMR LLC is a common occurrence in the biotechnology and pharmaceutical sectors, often reflecting long-term investment strategies in companies with promising pipelines or market positions. This filing primarily reflects an ownership disclosure rather than a strategic industry move.

Comparison to Industry Standards

• NA (This filing is a standard ownership disclosure and does not provide operational or financial results for comparison.)

Stakeholder Impact

• Shareholders: The continued significant ownership by a major institutional investor like FMR LLC may be viewed positively, potentially signaling stability and long-term investment interest.
• Management: The statement that the shares are held in the ordinary course of business and not for influencing control suggests no immediate pressure from this shareholder on management or strategic direction.

Key Dates

Recommendation

The filing indicates a stable, significant institutional ownership by FMR LLC, a major asset manager, in Day One Biopharmaceuticals Inc. This suggests a long-term investment perspective without any intent to influence control, which is generally a neutral to positive signal. However, as a Schedule 13G filing, it does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing fundamental analysis.

Keywords

Day One Biopharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals, Fidelity